R&D outsourcing and more with Pfizer’s former R&D head
Gil Y. Roth
11/14/11
I encountered John LaMattina’s pharma-blog, Drug Truths (johnlamattina.wordpress.com/), this summer after he penned an article in Nature Reviews Drug Discovery in which he discussed the chilling effects that large pharma mergers have on R&D. Dr. LaMattina wasn’t some random pharma-griper; he served as senior vice president, Pfizer and president, Pfizer Global R&D, the capstone of a 30-year career at the company, where he began as a medicinal chemist.
|
| Read More... |
|
Global Life Sciences Companies Turn to 3PLs
Scott Cubbler
11/14/11
Five years ago, large life sciences and pharmaceutical manufacturers typically built big, dedicated warehouse facilities to store their products before shipping them to customers. Very few outsourced distribution operations to third-party logistics (3PL) partners.
Times have changed. That is the conclusion drawn from an independent survey of large manufacturers recently commissioned by Exel and sister organization, DHL Supply Chain.
|
| Read More... |
|
Top 10 Mistakes Clients Make with their CMOs
Eric S. Langer
11/14/11
Bad relationships are rarely one-sided. This certainly holds true for the CMO-client relationship, where some might expect the service provider to do the heavy lifting in the alliance. According to data released in our 8th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production,1 that may not entirely be the case. It turns out that more than 9 in 10 CMOs have their own set of problems and reservations about their partners. Some problems are systemic, and not easily resolved with client services or improved management. For example, nearly all (92%) indicated that their ‘clients want to contain costs by doing limited development runs’. Yet, they still expect projects to be successful at full-scale manufacturing.
|
| Read More... |
|
Cardinal Health battling top competitors for huge VA contract
Brandon Glenn
11/28/11
Cardinal Health (NYSE:CAH) is staring down its top two competitors for a U.S. Department of Veterans Affairs (VA) drug distribution contract that could be worth up to $32 billion.
In January, Dublin, Ohio-based Cardinal should know whether it or AmerisourceBergen (NYSE:ABC) or McKesson (NYSE:MCK) has won the giant VA contract, Bloomberg News reported.
|
| Read More... |
|